Your browser doesn't support javascript.
loading
Carbonyl reductase 1 amplifies glucocorticoid action in adipose tissue and impairs glucose tolerance in lean mice.
Bell, Rachel M B; Villalobos, Elisa; Nixon, Mark; Miguelez-Crespo, Allende; Murphy, Lee; Fawkes, Angie; Coutts, Audrey; Sharp, Matthew G F; Koerner, Martha V; Allan, Emma; Meijer, Onno C; Houtman, Renè; Odermatt, Alex; Beck, Katharina R; Denham, Scott G; Lee, Patricia; Homer, Natalie Z M; Walker, Brian R; Morgan, Ruth A.
Afiliación
  • Bell RMB; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: rachel.bell@ed.ac.uk.
  • Villalobos E; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: evillalo@exseed.ed.ac.uk.
  • Nixon M; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: m.nixon@ed.ac.uk.
  • Miguelez-Crespo A; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: amiguele@exseed.ed.ac.uk.
  • Murphy L; Genetics Core, Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: lee.murphy@ed.ac.uk.
  • Fawkes A; Genetics Core, Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: a.fawkes@ed.ac.uk.
  • Coutts A; Genetics Core, Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: aduncan5@exceed.ed.ac.uk.
  • Sharp MGF; Transgenics Core, Bioresearch & Veterinary Services, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: matthew.sharp@ed.ac.uk.
  • Koerner MV; Transgenics Core, Bioresearch & Veterinary Services, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: m.koerner@ed.ac.uk.
  • Allan E; Transgenics Core, Bioresearch & Veterinary Services, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: emma.murdoch@igmm.ed.ac.uk.
  • Meijer OC; Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: o.c.meijer@lumc.nl.
  • Houtman R; Pamgene International, Den Bosch, the Netherlands. Electronic address: rene@precisionmedicinelab.nl.
  • Odermatt A; Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Electronic address: alex.odermatt@unibas.ch.
  • Beck KR; Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland. Electronic address: katharina.beck@wlab.gu.se.
  • Denham SG; Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: scott.denham@ed.ac.uk.
  • Lee P; Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: t.lee1@exceed.ed.ac.uk.
  • Homer NZM; Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: n.z.m.homer@ed.ac.uk.
  • Walker BR; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Clinical and Translational Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom. Electronic address: brian.walker@newcastle
  • Morgan RA; British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom; Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, United Kingdom. Electronic address: ruth.morgan@ed.ac.uk.
Mol Metab ; 48: 101225, 2021 06.
Article en En | MEDLINE | ID: mdl-33785425
ABSTRACT

OBJECTIVE:

Carbonyl reductase 1 (Cbr1), a recently discovered contributor to tissue glucocorticoid metabolism converting corticosterone to 20ß-dihydrocorticosterone (20ß-DHB), is upregulated in adipose tissue of obese humans and mice and may contribute to cardiometabolic complications of obesity. This study tested the hypothesis that Cbr1-mediated glucocorticoid metabolism influences glucocorticoid and mineralocorticoid receptor activation in adipose tissue and impacts glucose homeostasis in lean and obese states.

METHODS:

The actions of 20ß-DHB on corticosteroid receptors in adipose tissue were investigated first using a combination of in silico, in vitro, and transcriptomic techniques and then in vivo administration in combination with receptor antagonists. Mice lacking one Cbr1 allele and mice overexpressing Cbr1 in their adipose tissue underwent metabolic phenotyping before and after induction of obesity with high-fat feeding.

RESULTS:

20ß-DHB activated both the glucocorticoid and mineralocorticoid receptor in adipose tissue and systemic administration to wild-type mice induced glucose intolerance, an effect that was ameliorated by both glucocorticoid and mineralocorticoid receptor antagonism. Cbr1 haploinsufficient lean male mice had lower fasting glucose and improved glucose tolerance compared with littermate controls, a difference that was abolished by administration of 20ß-DHB and absent in female mice with higher baseline adipose 20ß-DHB concentrations than male mice. Conversely, overexpression of Cbr1 in adipose tissue resulted in worsened glucose tolerance and higher fasting glucose in lean male and female mice. However, neither Cbr1 haploinsfficiency nor adipose overexpression affected glucose dyshomeostasis induced by high-fat feeding.

CONCLUSIONS:

Carbonyl reductase 1 is a novel regulator of glucocorticoid and mineralocorticoid receptor activation in adipose tissue that influences glucose homeostasis in lean mice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Receptores de Glucocorticoides / Tejido Adiposo / Intolerancia a la Glucosa / Oxidorreductasas de Alcohol / Glucocorticoides / Obesidad Límite: Animals / Female / Humans / Male Idioma: En Revista: Mol Metab Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Transducción de Señal / Receptores de Glucocorticoides / Tejido Adiposo / Intolerancia a la Glucosa / Oxidorreductasas de Alcohol / Glucocorticoides / Obesidad Límite: Animals / Female / Humans / Male Idioma: En Revista: Mol Metab Año: 2021 Tipo del documento: Article